Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $717.2 million.

  • Ascendis Pharma A's Cash & Current Investments rose 1994.21% to $717.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $717.2 million, marking a year-over-year increase of 1994.21%. This contributed to the annual value of $696.2 million for FY2025, which is 1643.42% up from last year.
  • Per Ascendis Pharma A's latest filing, its Cash & Current Investments stood at $717.2 million for Q4 2025, which was up 1994.21% from $630.2 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Cash & Current Investments registered a high of $849.4 million during Q1 2022, and its lowest value of $278.6 million during Q2 2024.
  • For the 5-year period, Ascendis Pharma A's Cash & Current Investments averaged around $564.7 million, with its median value being $552.0 million (2025).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 4035.83% in 2023, then skyrocketed by 10074.2% in 2025.
  • Over the past 5 years, Ascendis Pharma A's Cash & Current Investments (Quarter) stood at $515.7 million in 2021, then dropped by 8.65% to $471.1 million in 2022, then dropped by 8.77% to $429.8 million in 2023, then surged by 39.13% to $597.9 million in 2024, then grew by 19.94% to $717.2 million in 2025.
  • Its last three reported values are $717.2 million in Q4 2025, $630.2 million for Q3 2025, and $559.2 million during Q2 2025.